FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIA	AL OWNERSHIP
-----------------------------------	--------------

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Hecht Peter M (Last) (First) (Middle) C/O CYCLERION THERAPEUTICS, INC. 245 FIRST STREET, 18TH FLOOR					Issuer Name and Ticker or Trading Symbol Cyclerion Therapeutics, Inc. [CYCN] Jate of Earliest Transaction (Month/Day/Year) 01/03/2022							S. Relationship of Reporting Person(s) to Issuer Check all applicable) X Director 10% Owner X Officer (give title Other (specify below) Chief Executive Officer							
(Street) CAMBR (City)	IDGE M	IA .	02142 (Zip)	4.								6. Lii	ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Trans Date (Month/I				е	action 2A. Deemed Execution Date, if any (Month/Day/Year)		, Transaction Disposed Code (Instr.		rities Acquired (A) o ed Of (D) (Instr. 3, 4				s lly ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
							Code	v	Amount	t (A) or (D)		Trar	Transaction(s) (Instr. 3 and 4)				(
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date if any (Month/Day/Yea	4. Transa Code 8)		Derivative		6. Date Exercisable a Expiration Date (Month/Day/Year)			nd 7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Prio Deriva Secur (Instr.	itive ity	9. Number derivative Securities Beneficia Owned Following Reported Transacti	ve es ially ng d	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code			Date Exercisable		opiration	Title	Amount or Number of Share	5	(In:		on(s)				
Employee Stock Option (Right to Buy)	\$1.78	01/03/2022		A		52,950		(1)	01	1/03/2032	Common Stock	52,950	\$(52,95	0	D		
Employee Stock Option (Right to Buy)	\$1.21	01/20/2022		A		430,000		(2)	01	./20/2032	Common Stock	430,00	0 \$6)	430,00	00	D		

Explanation of Responses:

- 1. The stock option vests and becomes exercisable as to 8.3333% of the shares of Common Stock on each monthly anniversary of January 3, 2022.
- 2. The stock option vests and becomes exercisable as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 20, 2022.

/s/ Gary J. Simon, Attorney-in-

Fact

** Signature of Reporting Person

01/24/2022

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.